Detalhe da pesquisa
1.
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
Mult Scler
; 30(6): 707-713, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456445
2.
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Eur J Neurol
; 31(6): e16250, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38549186
3.
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Mult Scler
; 29(7): 856-865, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165941
4.
Sars-CoV2 infection in pregnant women with multiple sclerosis.
Mult Scler
; 29(9): 1090-1098, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232279
5.
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Ann Neurol
; 89(4): 780-789, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33480077
6.
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180219
7.
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Mult Scler
; 28(7): 1034-1040, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34328824
8.
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
Mult Scler
; 28(13): 2106-2111, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35735030
9.
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis.
Eur J Neurol
; 29(2): 535-542, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735749
10.
Signs and symptoms of COVID-19 in patients with multiple sclerosis.
Eur J Neurol
; 29(12): 3728-3736, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36086905
11.
A real-world study of alemtuzumab in a cohort of Italian patients.
Eur J Neurol
; 29(1): 257-266, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34558755
12.
Lung involvement correlates with disability in MS patients with COVID-19 pneumonia.
Neurol Sci
; 43(12): 6657-6659, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962215
13.
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mult Scler
; 27(5): 790-794, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749910
14.
Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management.
Neurol Sci
; 42(4): 1515-1521, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33439393
15.
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 91(3): 271-277, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31974130
16.
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
Mult Scler
; 25(9): 1263-1272, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30044207
17.
Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.
J Neurovirol
; 23(5): 742-749, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28791614
18.
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 93(4): 448-450, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34408003
19.
Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.
Mult Scler
; 23(13): 1757-1761, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28080255
20.
Correction to: Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management.
Neurol Sci
; 42(4): 1637, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33483887